Sano GOLD
Research type
Research Study
Full title
At-home large scale genomic testing to establish phenotype(s) and pathogenesis of Long Covid: The Sano Genetics Of Long coviD (Sano-GOLD) study
IRAS ID
291221
Contact name
David Strain
Contact email
Sponsor organisation
Sano Genetics
Duration of Study in the UK
3 years, 0 months, 0 days
Research summary
Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus (SARS-CoV-2).
Most people infected with the SARS-CoV-2 virus will experience mild to moderate respiratory illness and recover without requiring special treatment. Older people, and those with underlying medical problems like cardiovascular disease, diabetes, chronic respiratory disease, and cancer are more likely to develop serious illness.
Some patients who are infected with SARS-CoV-2 will go on to develop Long Covid. “Long Covid” is a term being used to describe lasting effects of the infection or have had the usual symptoms beyond 12 weeks. It is known that the chances of getting most infectious diseases, including COVID 19, are affected by your environment and genes. Understanding the effect of genes could lead to better ways of predicting and treating long COVID in future.
We will be exploring the genetic susceptibility of those who have had Long Covid, and will generate a cohort of cases, for comparison with those affected by SARS-CoV-2 in different ways.
Given that population genotyping is not currently available, we will explore whether any of these genotypes are associated with definite phenotypes (physical characteristics) that may predict susceptibility to long COVID. We also want to detect any conditions or patterns of symptoms that predict different disease outcomes. We’d like to understand how genetics affects all of these.
This will be done by means of a simple self administered buccal (inside of mouth) swab, and 9mls of saliva. Some participants will also donate a small sample of blood, through a CE marked finger prick test at home in other to measure antibody levels and any other relevant indicators.REC name
Wales REC 6
REC reference
21/WA/0191
Date of REC Opinion
15 Jun 2021
REC opinion
Further Information Favourable Opinion